FDA approves VEPPANU (vepdegestrant), the first PROTAC therapy for ESR1 mutated metastatic breast cancer. Approval sets a new treatment class for a genetic subgroup that has had limited targeted ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with ...
An infectious disease expert has dismissed calls for more COVID vaccine makers to withdraw their jabs. Here’s why.
Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results